{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335010","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2026-08-05T20:02:14+00:00","discovered_at":"2026-08-05T20:03:07.668685+00:00","generated_at":"2026-08-05T20:03:14.318512+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M","bullets":["Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).","Gross margin 82% (up 200 bps); operating expenses +7% vs revenue +34% shows leverage.","Net loss $7.3M (improved 37%); Adjusted EBITDA loss $3.2M (improved 56%).","FY 2026 revenue guidance maintained at $108-114M (midpoint ~25% growth); gross margin ~80%.","Cash $30.0M, up 17% from Q1 2026; includes $6.5M from ATM program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335010","json":"https://secwatch.observer/filing/0001193125-26-335010.json","markdown":"https://secwatch.observer/filing/0001193125-26-335010.md","text":"https://secwatch.observer/filing/0001193125-26-335010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/0001193125-26-335010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/bdsx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:03:14.318512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}